Introductory Clause Example with 4 Variations from Business Contracts

This page contains Introductory clauses in business contracts and legal agreements. An example clause is provided at the top of the page, followed by clauses with minor variations. You can view the text differences by selecting the "Show Differences" option.
Introductory. Avidity Biosciences, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the “Underwriters,” or, each, an “Underwriter”), an aggregate of [•] shares of common stock, $0.0001 par value per share (the “Common Stock”) of the Company. The aggregate of [•] shares so proposed to be sold is hereinafter referred to as the “Firm Stock”. The Company also proposes to sell to the Underwriters, upon t...he terms and conditions set forth in Section 3 hereof, up to an additional [•] shares of Common Stock (the “Optional Stock”). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the “Stock”. Cowen and Company, LLC, SVB Leerink LLC, Credit Suisse Securities (USA) LLC and Wells Fargo Securities, LLC are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the “Representatives.” In the event that the Company has no subsidiaries, or only one subsidiary, then all references herein to “subsidiaries” of the Company shall be deemed to refer to no subsidiary, or such single subsidiary, mutatis mutandis. View More
Found in Avidity Biosciences, Inc. contract

Variations of a "Introductory" Clause from Business Contracts

Introductory. Avidity Biosciences, Inc., Angion Biomedica Corp., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the “Underwriters,” or, each, an “Underwriter”), an aggregate of [•] [·] shares of common stock, $0.0001 $0.01 par value per share (the “Common Stock”) of the Company. The aggregate of [•] [·] shares so proposed to be sold is hereinafter referred to as the “Firm Stock”. The Company also propos...es to sell to the Underwriters, upon the terms and conditions set forth in Section 3 hereof, up to an additional [•] [·] shares of Common Stock (the “Optional Stock”). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the “Stock”. Cowen and Company, LLC, SVB Leerink LLC, Credit Suisse Securities (USA) LLC (“Cowen”) and Wells Fargo Securities, LLC Stifel, Nicolaus & Company, Incorporated are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the “Representatives.” In the event that the Company has no subsidiaries, or only one subsidiary, then all references herein to “subsidiaries” of the Company shall be deemed to refer to no subsidiary, or such single subsidiary, mutatis mutandis. View More
Found in Angion Biomedica Corp. contract
Introductory. Avidity Biosciences, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the “Underwriters,” or, each, an “Underwriter”), an aggregate of [•] 12,000,000 shares of common stock, $0.0001 par value per share (the “Common Stock”) of the Company. The aggregate of [•] 12,000,000 shares so proposed to be sold is hereinafter referred to as the “Firm Stock”. The Company also proposes to sell to th...e Underwriters, upon the terms and conditions set forth in Section 3 hereof, up to an additional [•] 1,800,000 shares of Common Stock (the “Optional Stock”). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the “Stock”. Cowen and Company, LLC, SVB Leerink LLC, Credit Suisse Securities (USA) LLC Evercore Group L.L.C. and Wells Fargo Securities, LLC are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the “Representatives.” In the event that the Company has no subsidiaries, or only one subsidiary, then all references herein to “subsidiaries” of the Company shall be deemed to refer to no subsidiary, or such single subsidiary, mutatis mutandis. View More
Found in Avidity Biosciences, Inc. contract
Introductory. Avidity Aura Biosciences, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the “Underwriters,” or, each, an “Underwriter”), an aggregate of [•] shares of common stock, $0.0001 $[•] par value per share (the “Common Stock”) of the Company. The aggregate of [•] shares so proposed to be sold is hereinafter referred to as the “Firm Stock”. The Company also proposes to sell to the Underwrite...rs, upon the terms and conditions set forth in Section 3 hereof, up to an additional [•] shares of Common Stock (the “Optional Stock”). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the “Stock”. Cowen and Company, LLC, LLC (“Cowen”), SVB Leerink LLC, Credit Suisse Securities (USA) LLC (“SVB Leerink”) and Wells Fargo Securities, LLC Evercore Group L.L.C. (“Evercore”) are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the “Representatives.” In the event that the Company has no subsidiaries, or only one subsidiary, then all references herein to “subsidiaries” of the Company shall be deemed to refer to no subsidiary, or such single subsidiary, mutatis mutandis. View More
Found in Aura Biosciences, Inc. contract
Introductory. Avidity Aura Biosciences, Inc., a Delaware corporation (the “Company”), proposes to sell, pursuant to the terms of this Agreement, to the several underwriters named in Schedule A hereto (the “Underwriters,” or, each, an “Underwriter”), an aggregate of [•] 6,700,000 shares of common stock, $0.0001 $0.00001 par value per share (the “Common Stock”) of the Company. The aggregate of [•] 6,700,000 shares so proposed to be sold is hereinafter referred to as the “Firm Stock”. The Company also proposes t...o sell to the Underwriters, upon the terms and conditions set forth in Section 3 hereof, up to an additional [•] 1,005,000 shares of Common Stock (the “Optional Stock”). The Firm Stock and the Optional Stock are hereinafter collectively referred to as the “Stock”. “Stock.” SVB Securities LLC (“SVB Securities”), Cowen and Company, LLC, SVB Leerink LLC, Credit Suisse Securities (USA) LLC (“Cowen”) and Wells Fargo Securities, LLC Evercore Group L.L.C. (“Evercore”) are acting as representatives of the several Underwriters and in such capacity are hereinafter referred to as the “Representatives.” In the event that the Company has no subsidiaries, or only one subsidiary, then all references herein to “subsidiaries” of the Company shall be deemed to refer to no subsidiary, or such single subsidiary, mutatis mutandis. View More
Found in Aura Biosciences, Inc. contract